COMPASS PATHWAYS PLC - AMERICAN DEPOSITORY SHARES

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

19 дек 2023 16:05:00 Источник Nasdaq GlobeNewswire

Compass Pathways appoints Teri Loxam as Chief Financial Officer

07 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire

Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry

06 дек 2023 16:00:09 Источник Nasdaq GlobeNewswire

Compass Pathways to participate in upcoming Evercore investor conference

24 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

15 ноя 2023 04:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

02 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways announces CFO transition

26 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023

24 окт 2023 16:01:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

18 сен 2023 16:31:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

06 сен 2023 04:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming September investor conferences

29 авг 2023 16:30:50 Источник Nasdaq GlobeNewswire

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors

16 авг 2023 08:58:20 Источник Nasdaq GlobeNewswire

COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights  

03 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023

31 июл 2023 08:32:44 Источник Nasdaq GlobeNewswire

COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology

17 июл 2023 04:00:00 Источник Nasdaq GlobeNewswire

Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin

13 июл 2023 04:00:00 Источник Nasdaq GlobeNewswire

American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies

06 июл 2023 07:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital

05 июл 2023 07:00:35 Источник Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming Cantor Fitzgerald and HC Wainwright investor conferences

16 июн 2023 07:00:00 Источник Nasdaq GlobeNewswire

COMPASS Pathways' key patents upheld by the US Patent and Trademark Office

06 июн 2023 08:00:00 Источник Nasdaq GlobeNewswire